A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors.
Authors
Venugopal, BBaird, R
Kristeleit, R
Plummer, R
Cowan, Richard A
Stewart, A
Fourneau, N
Hellemans, P
Elsayed, Y
McClue, S
Smit, J
Forslund, A
Phelps, C
Camm, J
Evans, T
de Bono, J
Banerji, U
Affiliation
University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow; The Institute of Cancer Research/The Royal Marsden NHS Foundation Trust; UCL Cancer Institute; St. George's University of London, London; Northern Centre for Cancer Care, Freeman Hospital, Newcastle; The Christie NHS Foundation Trust, Manchester, United Kingdom; Janssen Research & Development, LLC, Beerse, Belgium; and Janssen Research & Development, LLC, Raritan, New Jersey.Issue Date
2013-08-01
Metadata
Show full item recordAbstract
To determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetic and pharmacodynamic profile of quisinostat, a novel hydroxamate, pan-histone deacetylase inhibitor (HDACi).Citation
A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors. 2013, 19 (15):4262-72 Clin Cancer ResJournal
Clinical Cancer ResearchDOI
10.1158/1078-0432.CCR-13-0312PubMed ID
23741066Type
ArticleLanguage
enISSN
1078-0432ae974a485f413a2113503eed53cd6c53
10.1158/1078-0432.CCR-13-0312
Scopus Count
Collections
Related articles
- Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I.
- Authors: Fouliard S, Robert R, Jacquet-Bescond A, du Rieu QC, Balasubramanian S, Loury D, Loriot Y, Hollebecque A, Kloos I, Soria JC, Chenel M, Depil S
- Issue date: 2013 Sep
- Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome.
- Authors: Child F, Ortiz-Romero PL, Alvarez R, Bagot M, Stadler R, Weichenthal M, Alves R, Quaglino P, Beylot-Barry M, Cowan R, Geskin LJ, Pérez-Ferriols A, Hellemans P, Elsayed Y, Phelps C, Forslund A, Kamida M, Zinzani PL
- Issue date: 2016 Jul
- First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors.
- Authors: Brunetto AT, Ang JE, Lal R, Olmos D, Molife LR, Kristeleit R, Parker A, Casamayor I, Olaleye M, Mais A, Hauns B, Strobel V, Hentsch B, de Bono JS
- Issue date: 2013 Oct 1
- First-in-human study of the toxicity, pharmacokinetics, and pharmacodynamics of CG200745, a pan-HDAC inhibitor, in patients with refractory solid malignancies.
- Authors: Kim KP, Park SJ, Kim JE, Hong YS, Lee JL, Bae KS, Cha H, Kwon SK, Ro S, Cho J, Kim TW
- Issue date: 2015 Oct
- Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial.
- Authors: Doi T, Hamaguchi T, Shirao K, Chin K, Hatake K, Noguchi K, Otsuki T, Mehta A, Ohtsu A
- Issue date: 2013 Feb